Bibliography: Geriatric Psychiatry

American Geriatrics Society 2012 Beers Criteria Update Expert Panel: American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012; 60:616–631

Billioti de Gage S, Bégaud B, Bazin F, Verdoux H, Dartigues JF, Pérès K, Kurth T, Pariente A: Benzodiazepine use and risk of dementia: prospective population based study. BMJ 2012; 345:e6231

Brodaty H, Arasaratnam C: Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am J Psychiatry 2012; 169:946–953

Büchtemann D, Luppa M, Bramesfeld A, Riedel-Heller S: Incidence of late-life depression: A systematic review. J Affect Disord 2012; 142:172–179

Byers AL, Arean PA, Yaffe K: Low use of mental health services among older Americans with mood and anxiety disorders. Psychiatr Serv 2012; 63:66–72

Corbett A, Smith J, Creese B, Ballard C: Treatment of behavioral and psychological symptoms of Alzheimer’s disease. Curr Treat Options Neurol 2012; 14:113–125

Cuijpers P, Beekman AT, Reynolds CF: Preventing depression: a global priority. JAMA 2012; 307:1033–1034

Gitlin LN, Kales HC, Lyketsos CG: Nonpharmacologic management of behavioral symptoms in dementia. JAMA 2012; 308:2020–2029

Huybrechts KF, Gerhard T, Crystal S, Olfson M, Avorn J, Levin R, Lucas JA, Schneeweiss S: Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ 2012; 344:e977

Huybrechts KF, Schneeweiss S, Gerhard T, Olfson M, Avorn J, Levin R, Lucas JA, Crystal S: Comparative safety of antipsychotic medications in nursing home residents. J Am Geriatr Soc 2012; 60:420–429

Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, Chiang C, Cunningham F, Schneider LS, Blow FC: Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry 2012; 169:71–79

Kaspers PJ, Pasman HR, Onwuteaka-Philipsen BD, Deeg DJ: Changes over a decade in end-of-life care and transfers during the last 3 months of life: A repeated survey among proxies of deceased older people. Palliat Med Sep 17, 2012 [Epub ahead of print]

Lachner C, Steinle NI, Regenold WT: The neuropsychiatry of vitamin B12 deficiency in elderly patients. J Neuropsychiatry Clin Neurosci 2012; 24:5–15

Maher AR, Theodore G: Summary of the comparative effectiveness review on off-label use of atypical antipsychotics. J Manag Care Pharm 2012; 18(5, suppl B):S1–S20

Mohamed S, Rosenheck R, Lyketsos CG, Kaczynski R, Sultzer DL, Schneider LS: Effect of second-generation antipsychotics on caregiver burden in Alzheimer’s disease. J Clin Psychiatry 2012; 73:121–128

Naylor MD, Karlawish JH, Arnold SE, Khachaturian AS, Khachaturian ZS, Lee VM, Baumgart M, Banerjee S, Beck C, Blennow K, Brookmeyer R, Brunden KR, Buckwalter KC, Comer M, Covinsky K, Feinberg LF, Frisoni G, Green C, Guimaraes RM, Gwyther LP, Hefti FF, Hutton M, Kawas C, Kent DM, Kuller L, Langa KM, Mahley RW, Maslow K, Masters CL, Meier DE, Neumann PJ, Paul SM, Petersen RC, Sager MA, Sano M, Schenk D, Soares H, Sperling RA, Stahl SM, van Deerlin V, Stern Y, Weir D, Wolk DA, Trojanowski JQ: Advancing Alzheimer’s disease diagnosis, treatment, and care: recommendations from the Ware Invitational Summit. Alzheimers Dement 2012; 8:445–452

Schwarz S, Froelich L, Burns A: Pharmacological treatment of dementia. Curr Opin Psychiatry 2012; 25:542–550

Shahnawaz Z, Reppermund S, Brodaty H, Crawford JD, Draper B, Trollor JN, Sachdev PS: Prevalence and characteristics of depression in mild cognitive impairment: the Sydney Memory and Ageing Study. Acta Psychiatr Scand (Epub ahead of print Sep 4, 2012; doi: 10.1111/acps.12008)

Sheline YI, Disabato BM, Hranilovich J, Morris C, D’Angelo G, Pieper C, Toffanin T, Taylor WD, Macfall JR, Wilkins C, Barch DM, Welsh-Bohmer KA, Steffens DC, Krishnan RR, Doraiswamy PM: Treatment course with antidepressant therapy in late-life depression. Am J Psychiatry (Epub ahead of print Oct 3, 2012; doi: 10.1176/appi.ajp.2012.12010122)

Singh-Manoux A, Kivimaki M, Glymour MM, Elbaz A, Berr C, Ebmeier KP, Ferrie JE, Dugravot A: Timing of onset of cognitive decline: results from Whitehall II prospective cohort study. BMJ 2012; 344:d7622

Steinberg M, Lyketsos CG: Atypical antipsychotic use in patients with dementia: managing safety concerns. Am J Psychiatry 2012; 169:900–906

Unützer J, Park M: Older adults with severe, treatment-resistant depression. JAMA 2012; 308:909–918

van der Linde RM, Stephan BC, Matthews FE, Brayne C, Savva GM; on behalf of the Medical Research Council Cognitive Function and Ageing Study: The presence of behavioural and psychological symptoms and progression to dementia in the cognitively impaired older population. Int J Geriatr Psychiatry (Epub ahead of print Aug 10, 2012; doi: 10.1002/gps.3873)

Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev. 2012 Mar 14;3:CD006504.

Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH: The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7:270–279

Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, Bentham P, Fox C, Holmes C, Katona C, Knapp M, Lawton C, Lindesay J, Livingston G, McCrae N, Moniz-Cook E, Murray J, Nurock S, Orrell M, O’Brien J, Poppe M, Thomas A, Walwyn R, Wilson K, Burns A: Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 2011; 378:403–411

Cooper C, Katona C, Lyketsos K, Blazer D, Brodaty H, Rabins P, de Mendonça Lima CA, Livingston G: A systematic review of treatments for refractory depression in older people. Am J Psychiatry 2011; 168:681–688

Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J: Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 2011; 343:d4551

Huybrechts KF, Rothman KJ, Silliman RA, Brookhart MA, Schneeweiss S: Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. CMAJ 2011; 183:E411–E419

Jeste DV, Wolkowitz OM, Palmer BW: Divergent trajectories of physical, cognitive, and psychosocial aging in schizophrenia. Schizophr Bull 2011; 37:451–455

Kim HM, Chiang C, Kales HC: After the black box warning: predictors of psychotropic treatment choices for older patients with dementia. Psychiatr Serv 2011; 62:1207–1214

Maglione M, Maher AR, Hu J, Wang Z, Shanman R, Shekelle PG, Roth B, Hilton L, Suttorp MJ, Ewing BA, Motala A, Perry T: Off-Label Use of Atypical Antipsychotics: An Update. Rockville, Md, Agency for Healthcare Research and Quality, 2011

Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle PG: Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011; 306:1359–1369

O’Brien JT, Burns A, Ashley P, Bullock R, Burn D, Holmes C, Iliffe S, Jones R, McKeith I, Passmore P, Purandare N, Ritchie CW, Skoog I, Thomas A, Wilcock G, Wilkinson D; BAP Dementia Consensus Group: Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol 2011; 25:997–1019

Reynolds CF, Butters MA, Lopez O, Pollock BG, Dew MA, Mulsant BH, Lenze EJ, Holm M, Rogers JC, Mazumdar S, Houck PR, Begley A, Anderson S, Karp JF, Miller MD, Whyte EM, Stack J, Gildengers A, Szanto K, Bensasi S, Kaufer DI, Kamboh MI, DeKosky ST: Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. Arch Gen Psychiatry 2011; 68:51–60

Templeman K, Robinson A: Integrative medicine models in contemporary primary health care. Complement Ther Med 2011; 19:84–92

van’t Veer-Tazelaar PJ, van Marwijk HW, van Oppen P, van der Horst HE, Smit F, Cuijpers P, Beekman AT: Prevention of late-life anxiety and depression has sustained effects over 24 months: a pragmatic randomized trial. Am J Geriatr Psychiatry 2011; 19:230–239

Vigen CL, Mack WJ, Keefe RS, Sano M, Sultzer DL, Stroup TS, Dagerman KS, Hsiao JK, Lebowitz BD, Lyketsos CG, Tariot PN, Zheng L, Schneider LS: Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease: outcomes from CATIE-AD. Am J Psychiatry 2011; 168:831–839

Areán PA, Raue P, Mackin RS, Kanellopoulos D, McCulloch C, Alexopoulos GS: Problem-solving therapy and supportive therapy in older adults with major depression and executive dysfunction. Am J Psychiatry 2010; 167:1391–1398

Dombrovski AY, Clark L, Siegle GJ, Butters MA, Ichikawa N, Sahakian BJ, Szanto K: Reward/Punishment reversal learning in older suicide attempters. Am J Psychiatry 2010; 167:699–707

Conwell Y, Duberstein PR, Hirsch JK, Conner KR, Eberly S, Caine ED: Health status and suicide in the second half of life. Int J Geriatr Psychiatry 2010; 25:371–379

Alexopoulos GS, Kelly RE Jr: Research advances in geriatric depression. World Psychiatry 2009; 8:140–149

Alexopoulos GS, Reynolds CF, Bruce ML, Katz IR, Raue PJ, Mulsant BH, Oslin DW, Ten Have T; PROSPECT Group: Reducing suicidal ideation and depression in older primary care patients: 24-month outcomes of the PROSPECT study. Am J Psychiatry 2009; 166:882–890

Anisman H: Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder. J Psychiatry Neurosci 2009; 34:4–20

Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, Gill R, Juszczak E, Yu LM, Jacoby R; DART-AD investigators: The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 2009; 8:151–157

Mendez M: Frontotemporal dementia: therapeutic interventions. Front NeurolNeurosci. vol. 24. Basel, Karger, 2009, pp 168–178

O'Connor DW, Ames D, Gardner B, King M: Psychosocial treatments of behavior symptoms in dementia: a systematic review of reports meeting quality standards. International Psychogeriatrics 2009; 21:225–240

Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A, Hammad TA, Temple R, Rochester G: Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 2009; 339:b2880

van’t Veer-Tazelaar PJ, van Marwijk HW, van Oppen P, van Hout HP, van der Horst HE, Cuijpers P, Smit F, Beekman AT: Stepped-care prevention of anxiety and depression in late life: a randomized controlled trial. Arch Gen Psychiatry 2009; 66:297–304

Zheng L, Mack WJ, Dagerman KS, Hsiao JK, Lebowitz BD, Lyketsos CG, Stroup TS, Sultzer DL, Tariot PN, Vigen C, Schneider LS: Metabolic changes associated with second-generation antipsychotic use in Alzheimer’s disease patients: the CATIE-AD study. Am J Psychiatry 2009; 166:583–590

Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001191.

Cuijpers P, van Straten A, Smit F, Mihalopoulos C, Beekman A: Preventing the onset of depressive disorders: a meta-analytic review of psychological interventions. Am J Psychiatry 2008; 165:1272–1280

FDA: Information for Healthcare Professionals: Conventional Antipsychotics 2008 [updated 06/16/200809/19/12]. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124830.htm.

Jeste DV, Blazer D, Casey D, Meeks T, Salzman C, Schneider L, Tariot P, Yaffe K: ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 2008; 33:957–970

Nelson JC, Delucchi K, Schneider LS: Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence. Am J Geriatr Psychiatry 2008; 16:558–567

Robinson RG, Jorge RE, Moser DJ, Acion L, Solodkin A, Small SL, Fonzetti P, Hegel M, Arndt S: Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. JAMA 2008; 299:2391–2400

Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, Rosenheck RA, Hsiao JK, Lieberman JA, Schneider LS; CATIE-AD Study Group: Clinical symptom responses to atypical antipsychotic medications in Alzheimer’s disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 2008; 165:844–854

Valiyeva E, Herrmann N, Rochon PA, Gill SS, Anderson GM: Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. CMAJ 2008; 179:438–446

Rovner BW, Casten RJ, Hegel MT, Leiby BE, Tasman WS: Preventing depression in age-related macular degeneration. Arch Gen Psychiatry 2007; 64:886–892

American Psychiatric Association, Treatment of Patients with Alzheimer's Disease and Other Dementias, Second Edition (2007) http://psychiatryonline.org/guidelines.aspx

Reynolds CF, Dew MA, Pollock BG, Mulsant BH, Frank E, Miller MD, Houck PR, Mazumdar S, Butters MA, Stack JA, Schlernitzauer MA, Whyte EM, Gildengers A, Karp J, Lenze E, Szanto K, Bensasi S, Kupfer DJ: Maintenance treatment of major depression in old age. N Engl J Med 2006; 354:1130–1138

FDA: Public health advisory: Deaths with antipsychotics in elderly patients with behavioral disturbances. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053171.htm2005 [updated April 11, 2005; cited 2012 09/17/12].

Livingston G, Johnston K, Katona C, Paton J, Lyketsos CG; Old Age Task Force of the World Federation of Biological Psychiatry: Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry 2005; 162:1996–2021